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CASE REPORT
Toxic Epidermal Necrolysis Associated with Sorafenib 
and Tosufloxacin in a Patient with Hepatocellular 
Carcinoma
Mun Ki Choi, M.D.*, Hyun Young Woo, M.D.*, Jeong Heo, M.D., Mong Cho, M.D., 
Gwang Ha Kim, M.D., Geun Am Song, M.D., Moon Bum Kim, M.D.
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Departments of Internal Medicine, 
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This is the first case report to describe a 44-year-old woman 
with a history of advanced hepatocellular carcinoma who 
developed toxic epidermal necrolysis (TEN) clinically after 
taking 400 mg sorafenib (Nexavar
Ⓡ, BAY 43-9006) and 
tosufloxacin orally once per day. Both sorafenib and 
tosufloxacin were eventually discontinued, and the TEN 
resolved with corticosteroids and supportive treatment. 
Clinical physicians should be aware of this possible 
complication so that early interventions can be made. (Ann 
Dermatol 23(S3) S404∼S407, 2011)
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INTRODUCTION
Adverse cutaneous reactions to drugs are common occur-
rences in 2∼3% of hospitalized patients
1. Severe drug 
reaction patterns include angioedema, anaphylaxis, exfo-
liative dermatitis, drug hypersensitivity syndrome, Stevens- 
Johnson syndrome (SJS), and toxic epidermal necrolysis 
(TEN). TEN, which is a rare but potentially life-threatening 
condition, is associated with medications, including sulfo-
namides, penicillin, and other antibiotics, anticonvulsants, 
non steroidal anti-inflammatory drugs, allopurinol, and 
corticosteroids. Herein, we report a case of a patient diag-
nosed with sorafenib (Nexavar, Bayer HealthCare Pharma-
ceuticals-Onyx Pharmaceuticals) and tosufloxacin-induced 
TEN who was successfully treated with corticosteroids. To 
our knowledge, TEN associated with sorafenib and tosu-
floxacin has never been previously discussed in the 
literature.
CASE REPORT
A 44-year-old woman presented 3 years ago because of 
chronic hepatitis B-related liver cirrhosis with advanced 
multifocal hepatocellular carcinoma (HCC). The stage of 
liver cirrhosis was Child-Pugh’s functional class A. She 
had received 12 sessions of transcatheter arterial chemo-
embolization (TACE) repeatedly and one session of radio-
frequency ablation since the HCC diagnosis. In combina-
tion with TACE, she had also been treated with sorafenib, 
which is a tyrosine-kinase inhibitor, at the reduced dose of 
200 mg orally twice per day since 2008. Two months 
prior to admission, she underwent percutaneous drainage 
combined with broad spectrum antibiotics (third genera-
tion cephalosporin and cefotaxime) because of an infected 
intrahepatic biloma secondary to frequent TACE. At that 
time, the sorafenib therapy was temporarily discontinued. 
The infected intrahepatic biloma was cured by the above 
mentioned treatment after 1 month, then administration of 
sorafenib was restarted at 400 mg once daily, and intrave-Toxic Epidermal Necrolysis Associated with Sorafenib and Tosufloxacin
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Fig. 1. Picture of the patient at ad-
mission. (A) Confluent and erythe-
matous macules on the face (A) 
with numerous and widespread 
sheets of flaccid blistering with 
positive Nikolsky’s sign on the arm
and leg (B∼D). 
nous antibiotics were switched to oral tosufloxacin (Ozex, 
SK Chemicals, Seoul, Korea) at 150 mg twice daily.
About 2 weeks after restarting the sorafenib, she was 
admitted to the emergency department for a generalized 
erythematous rash and fever. On physical examination, 
erythematous macules were confluent on ＞80% of the 
total body surface with numerous and widespread sheets 
of flaccid blistering (Fig. 1). Nikolsky’s sign was positive. 
There were also hemorrhagic crusts on the lips and 
erosions involving the tongue, oral mucosa, but not the 
conjunctiva. She evolved rapidly with increased epider-
mal detachment in the face, neck, thorax, dorsum, and 
limbs, affecting more than 30% of her body. The patient 
presented with a temperature of 38.2
oC without localized 
signs of infection. Laboratory studies were normal except 
for a slightly high C-reactive protein of 3.55 mg/dl (nor-
mal, 0∼0.5 mg/dl) and an elevated lactate dehydrogenase 
of 1,017 IU/L (normal range, 95∼280 IU/L). Her other 
medications on admission, included lamivudine, ursode-
oxycholic acid, mecobalamin, thiamine, gabapentin, oxy-
codone, and tosufloxacin, which she had taken for over 2 
years without any recent change in dose except for the 
tosufloxacin. The diagnosis of drug-induced TEN was 
made based on the clinical history and sorafenib and 
tosufloxacin administration, which was strongly suspected 
as the offending medication, and was withdrawn imme-
diately. Tosufloxacin was also discontinued because of the 
possibility of being the culprit drug. The exposed dermis 
and eroded mucosal surface were protected with polyure-
thane foam (Medifoam, DongSung Biopol, Seoul, Korea) 
and wet gauze. Intravenous hydration and total parenteral 
nutrition was continued until oral intake was possible 
without oral pain. She received corticosteroid therapy, 
given initially as intravenous 5 mg dexamethasone daily 
and later changed to oral prednisolone. New epithelializa-
tion appeared within 15 days, and the lesions gradually 
resolved (Fig. 2), but hyperpigmentation in the involved 
areas remained. The patient was discharged with normal 
oral feeding 8 weeks after admission. She has remained in 
good health without recurrence of symptoms during 8 
months of follow-up.
DISCUSSION
TEN, also known as Lyell’s syndrome, is a rare disease of 
unclear pathophysiology, and its incidence is estimated to 
be 1.5∼2 new cases per million population per year
1. 
The disorder seems to be more common among patients 
with human immunodeficiency virus infection, systemic 
lupus erythematosus, and malignancy
2. TEN is a cutaneous MK Choi, et al
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Fig. 2. Picture of the patient 2 
weeks after beginning steroid treat-
ment. The skin lesions had resol-
ved but hyperpigmentation remain-
ed. 
reaction to various precipitating agents, characterized by 
sudden apoptosis of keratinocytes leading to widespread 
erythema, mucous membrane erosion, extensive epider-
mal detachment, and severe constitutional symptoms
1,3. 
Within this spectrum of epidermal necrolysis, detachment 
of ＜10% of the total body surface area defines SJS. When 
＞30%, it is defined as TEN, whereas intermediate cases 
are an overlap of SJS-TEN
4. Many factors have been 
proposed as causes of TEN, including adverse reactions to 
drugs, infections, malignant disorders, and graft-versus-host 
disease
5,6. However, most case reports and studies suggest 
that TEN is usually an idiosyncratic hypersensitivity to 
medication
7,8. TEN is a serious diseases, considering the 
severity of systemic manifestations, the unpredictable evo-
lution, and the absence of specific therapy. 
The diagnosis should be confirmed by skin biopsy 
showing full thickness necrosis of the epidermis, but, in 
this case, a skin biopsy was missed unfortunately. Instead, 
the diagnosis of TEN in our case was based on clinical 
features which showed skin detachment of ＞30% of the 
total body surface area and involvement of mucous 
membranes. The cause of TEN in our case was considered 
to be a drug. The most suspected drugs in our patient 
were sorafenib and tosufloxacin, considering a close 
temporal correlation between drug exposure and the onset 
of symptoms. The typical interval between the first drug 
intake and onset of symptoms is between 1 and 3 weeks
9. 
In this case, the characteristic symptoms appeared 2 
weeks after restarting sorafenib and tosufloxacin. It 
remains doubtful why TEN did not occur during the 1.5 
years between the initial sorafenib administration and the 
temporal discontinuation of sorafenib. This was too long 
to accept as a period of sensitization. Concomitant oral 
tosufloxacin may have increased the blood level of 
sorafenib by inhibiting sorafenib metabolism in the liver. 
Both drugs are metabolized by cytochrome P-450 family 
enzymes in the liver. Other drugs might be questioned, 
but the patient had received these drugs for 2 years and 
these medications were well tolerated and no adverse 
cutaneous reaction had developed. Sorafenib and tosu-
floxacin were the only drugs added before the cutaneous 
lesions appeared.
The pathophysiological mechanisms of TEN remain un-
known, but several studies support the hypothesis of an 
immune mediation. TEN is thought to be initiated by an 
immune response to an antigenic complex formed by the 
reaction of drug metabolites with certain host tissues
10-12. 
Genetic susceptibility including HLA genotype might also 
play a role
13. 
There is no specific treatment for TEN. Discontinuation of 
the culprit drug is the first step for managing these 
patients. Additionally, supportive care, including wound 
care, hydration, and nutritional support forms the basis of 
treatment. The role of corticosteroids in TEN remains 
controversial. Although some studies have suggested that 
systemic corticosteroids are mandatory and life-saving
14, 
other studies do not recommend their, because corticos-
teroids may increase the risk for infection, delay healing, 
mask early signs of sepsis, and induce severe gastroin-
testinal bleeding
15. We observed the efficacy and safety of 
corticosteroids administered at an early stage of TEN in 
our patient. 
The SCORTEN, a severity-of-illness score for TEN, is an 
accurate predictor of mortality in patients with TEN
16. Toxic Epidermal Necrolysis Associated with Sorafenib and Tosufloxacin
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Seven predictive factors are included, such as age, malig-
nancy, body surface area detached, tachycardia, serum 
urea, glucose and bicarbonate. The calculated SCORTEN 
during the first 24 hours of admission was 3 with a 
predicted mortality of 35.3%.
Sorafenib, which has gained widespread use in the 
treatment of advanced HCC, has a good safety profile. The 
most common cutaneous side effects include skin rash 
with or without desquamation, alopecia, pruritus, dry 
skin, and hand-foot skin reactions
17. Severe skin manifes-
tations such as TEN, as shown in this case, have never 
been reported. We suspect that tosufloxacin may have 
contributed to the development of the skin manifestation 
by altering sorafenib metabolism. Therefore, physicians 
should be aware of this possible complication, so that 
early interventions can be made. 
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